Omnicell, Inc. $OMCL Shares Sold by Pier Capital LLC

Pier Capital LLC reduced its position in Omnicell, Inc. (NASDAQ:OMCL) by 34.6% in the 3rd quarter, according to its most recent filing with the SEC. The firm owned 115,714 shares of the company’s stock after selling 61,211 shares during the period. Pier Capital LLC’s holdings in Omnicell were worth $3,523,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of OMCL. WINTON GROUP Ltd acquired a new position in Omnicell in the second quarter valued at $2,692,000. Advantage Alpha Capital Partners LP purchased a new position in Omnicell during the second quarter worth about $2,476,000. Assenagon Asset Management S.A. boosted its stake in Omnicell by 1,316.2% in the 3rd quarter. Assenagon Asset Management S.A. now owns 140,675 shares of the company’s stock worth $4,284,000 after buying an additional 130,742 shares during the last quarter. Acadian Asset Management LLC boosted its stake in Omnicell by 33.9% in the 2nd quarter. Acadian Asset Management LLC now owns 168,519 shares of the company’s stock worth $4,946,000 after buying an additional 42,676 shares during the last quarter. Finally, Capital Fund Management S.A. grew its holdings in Omnicell by 97.1% in the 2nd quarter. Capital Fund Management S.A. now owns 44,713 shares of the company’s stock valued at $1,315,000 after buying an additional 22,031 shares during the period. 97.70% of the stock is currently owned by institutional investors and hedge funds.

Omnicell Stock Performance

Omnicell stock opened at $35.10 on Friday. The company has a market cap of $1.59 billion, a price-to-earnings ratio of 877.72, a price-to-earnings-growth ratio of 1.34 and a beta of 0.79. Omnicell, Inc. has a 12 month low of $22.66 and a 12 month high of $55.00. The company has a debt-to-equity ratio of 0.14, a current ratio of 1.43 and a quick ratio of 1.22. The stock’s 50-day moving average is $43.98 and its 200-day moving average is $38.42.

Omnicell (NASDAQ:OMCL) last issued its earnings results on Thursday, February 5th. The company reported $0.40 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.47 by ($0.07). The firm had revenue of $313.98 million for the quarter, compared to analysts’ expectations of $313.36 million. Omnicell had a return on equity of 3.00% and a net margin of 0.17%.The firm’s revenue for the quarter was up 2.3% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.60 EPS. Omnicell has set its Q1 2026 guidance at 0.260-0.360 EPS and its FY 2026 guidance at 1.650-1.850 EPS. Equities analysts anticipate that Omnicell, Inc. will post 1.09 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of research firms have recently commented on OMCL. Bank of America raised shares of Omnicell from a “neutral” rating to a “buy” rating and set a $70.00 price objective for the company in a research note on Wednesday, February 4th. Wall Street Zen cut shares of Omnicell from a “buy” rating to a “hold” rating in a research report on Saturday, February 7th. Weiss Ratings downgraded shares of Omnicell from a “hold (c-)” rating to a “sell (d)” rating in a report on Monday, March 2nd. KeyCorp raised shares of Omnicell from a “sector weight” rating to an “overweight” rating and set a $60.00 price target on the stock in a research note on Wednesday, January 7th. Finally, Piper Sandler reiterated an “overweight” rating and issued a $49.00 price target (down from $63.00) on shares of Omnicell in a report on Friday, February 6th. Five investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, Omnicell currently has an average rating of “Moderate Buy” and an average price target of $54.50.

Insider Transactions at Omnicell

In other Omnicell news, EVP Corey J. Manley sold 6,106 shares of the business’s stock in a transaction that occurred on Thursday, January 8th. The shares were sold at an average price of $49.90, for a total transaction of $304,689.40. Following the completion of the sale, the executive vice president directly owned 91,674 shares in the company, valued at $4,574,532.60. The trade was a 6.24% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 2.52% of the stock is currently owned by corporate insiders.

Omnicell Profile

Omnicell, Inc is a healthcare technology company that specializes in medication management solutions for hospitals, clinics and pharmacies. The company’s offerings encompass automated dispensing cabinets, pharmacy automation systems, IV compounding devices, and software platforms designed to optimize medication usage, streamline workflow and improve patient safety. Omnicell’s analytics and inventory management tools provide real-time visibility into medication utilization, helping healthcare providers reduce waste, manage controlled substances and ensure regulatory compliance.

Founded in Mountain View, California in 1992, Omnicell has grown through both internal innovation and strategic acquisitions to broaden its portfolio across the medication management continuum.